cas 6148-64-7|| where to buy Potassium 3-ethoxy-3-oxopropanoate

Nom du produit:Potassium 3-ethoxy-3-oxopropanoate

IUPAC Name:potassium 3-ethoxy-3-oxopropanoate

Unité d'emballage	Stock disponible	Prix($)	Quantité
CM254041-1000g	in stock	ƞź

Pour une utilisation en R&D uniquement..

Formulaire de demande

Nom chimique

Numéro CAS

Quantité*

Spécifications requises*
(% d'analyse, qualité du matériau, etc.)

Nom du contact*

Email du contact*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 6148-64-7 regularly via the above email.

Notes supplémentaires

Verification code*

refresh

: N° CAS:6148-64-7; Formule moléculaire:C5H7KO4; Point de fusion:-; Code SMILES:O=C([O-])CC(OCC)=O.[K+]; Densité:

: Numéro de catalogue:CM254041; Poids moléculaire:170.21; Point d'ébullition:297.3°C at 760 mmHg; N° Mdl:MFCD00035603; Stockage:Keep in a tight container and store at ambient temperature

: Aliphatic Chain Compounds; Aliphatic chain compounds include aliphatic compounds and chain compounds containing other elements or groups. Aliphatic hydrocarbons are hydrocarbons with the basic properties of aliphatic compounds. In aliphatic compounds, carbon atoms are arranged in straight chain, branched chain or cyclic, which are respectively called straight chain aliphatic hydrocarbons, branched chain aliphatic hydrocarbons and alicyclic hydrocarbons. Some cyclic hydrocarbons are different in nature from aromatic hydrocarbons, and are very similar to aliphatic hydrocarbons. Such cyclic hydrocarbons are called alicyclic hydrocarbons. In this way, aliphatic hydrocarbons become a general term for all hydrocarbons except aromatic hydrocarbons. Aliphatic hydrocarbons and their derivatives (including halogenated hydrocarbons) and alicyclic hydrocarbons and their derivatives are collectively referred to as aliphatic compounds.

: BNC-210; Bionomics Ltd.’s drug candidate, BNC-210 would be advanced into Phase 3 studies in Social Anxiety Disorder (SAD) after the successful End-of-Phase 2 Meeting with the U.S. FDA in September. BNC-210 has a unique action potential that depends on acetylcholine neurotransmission and allosteric modulation of α7 nAChR. It is designed to treat patients with serious central nervous system (CNS) disorders with limited side effects. BNC-210 received Fast-Track designation from the FDA for the acute treatment of SAD.